Nongastric marginal-zone B-cell MALT lymphoma: Prognostic value of disease dissemination

被引:54
作者
Arcaini, Luca
Burcheri, Sara
Rossi, Andrea
Passamonti, Francesco
Paulli, Marco
Boveri, Emanuela
Brusamolino, Ercole
Orlandi, Ester
Molteni, Alfredo
Pulsoni, Alessandro
Cox, Maria Christina
Orsucci, Lorella
Fabbri, Alberto
Frezzato, Maurizio
Voso, Maria Teresa
Zaja, Francesco
Montanari, Francesca
Pascutto, Cristiana
Morra, Enrica
Cortelazzo, Sergio
Lazzarino, Mario
机构
[1] Univ Pavia, IRCCS, Policlin San Matteo, Div Hematol, I-27100 Pavia, Italy
[2] Univ Pavia, IRCCS, Policlin San Matteo, Dept Pathol, I-27100 Pavia, Italy
[3] Osped Riuniti Bergamo, Div Hematol, I-24100 Bergamo, Italy
[4] Osped Niguarda Ca Granda, Div Hematol, Milan, Italy
[5] Univ Roma La Sapienza, Dept Hematol, Rome, Italy
[6] Univ Roma La Sapienza, Azienda Osped S Andrea, Rome, Italy
[7] Azienda Osped S Giovanni Battista, Div Hematol, Turin, Italy
[8] Univ Siena, Div Hematol, Policlin S Maria Scotte, I-53100 Siena, Italy
[9] San Bortolo Hosp, Dept Hematol, Vicenza, Italy
[10] Catholic Univ, Sch Med, Dept Hematol, Rome, Italy
[11] Univ Udine, Div Hematol, I-33100 Udine, Italy
关键词
MALT lymphoma; prognosis; marginal zone; dissemination;
D O I
10.1634/theoncologist.11-3-285
中图分类号
R73 [肿瘤学];
学科分类号
100214 [肿瘤学];
摘要
The aim of this study is to describe the clinical features and define the prognostic significance of disease dissemination in a large series of nongastric marginal-zone B-cell mucosa-associated lymphoid tissue (MALT) lymphomas. We studied 208 patients with nongastric marginal-zone B-cell MALT lymphoma diagnosed and treated from 1991 to 2004. Ninety percent of the patients had a single site of MALT involvement-skin (26%), salivary glands (18%), orbit (14%), Waldeyer's ring (13%)-and 39% and 28% had nodal involvement and bone marrow involvement, respectively. After a median follow-up of 2.7 years, the median event-free survival (EFS) time was 2.4 years, and the median overall survival (OS) time was not reached. On univariate analysis, the features significantly associated with longer EFS and OS times were the following: single MALT site involvement (OS), localized disease (EFS and OS), no nodal disease (EFS and OS), skin and orbit lymphoma (OS), and stage IV disease without bone marrow involvement (OS). On multivariate analysis, both bone marrow and nodal involvement were associated with shorter OS. This study describes the clinical features and the natural history of nongastric marginal-zone lymphomas and highlights that the dissemination to lymph nodes and bone marrow is associated with a poorer outcome.
引用
收藏
页码:285 / 291
页数:7
相关论文
共 18 条
[1]
State-of-the-art therapeutics: Marginal-zone lymphoma [J].
Bertoni, F ;
Zucca, E .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (26) :6415-6420
[2]
Cavalli F, 2001, Hematology Am Soc Hematol Educ Program, P241
[3]
Chan WC, 1997, BLOOD, V89, P3909
[4]
Clinical activity of rituximab in extranodal marginal zone B-cell lymphoma of MALT type [J].
Conconi, A ;
Martinelli, G ;
Thiéblemont, C ;
Ferreri, AJM ;
Devizzi, L ;
Peccatori, F ;
Ponzoni, M ;
Pedrinis, E ;
Dell'Oro, S ;
Pruneri, G ;
Filipazzi, V ;
Dietrich, PY ;
Gianni, AM ;
Coiffier, B ;
Cavalli, F ;
Zucca, E .
BLOOD, 2003, 102 (08) :2741-2745
[5]
Harris N L, 2000, Hematol J, V1, P53, DOI 10.1038/sj.thj.6200013
[6]
Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma [J].
O'Connor, OA ;
Wright, J ;
Moskowitz, C ;
Muzzy, J ;
MacGregor-Cortelli, B ;
Stubblefield, M ;
Straus, D ;
Portlock, C ;
Hamlin, P ;
Choi, E ;
Dumetrescu, O ;
Esseltine, D ;
Trehu, E ;
Adams, J ;
Schenkein, D ;
Zelenetz, AD .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (04) :676-684
[7]
Phase II study of oxaliplatin for treatment of patients with mucosa-associated lymphoid tissue lymphoma [J].
Raderer, M ;
Wöhrer, S ;
Bartsch, R ;
Prager, G ;
Drach, J ;
Hejna, M ;
Gaiger, A ;
Turetschek, K ;
Jaeger, U ;
Streubel, B ;
Zielinski, CC .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (33) :8442-8446
[8]
Importance of extensive staging in patients with mucosa-associated lymphoid tissue (MALT)-type lymphoma [J].
Raderer, M. ;
Vorbeck, F. ;
Formanek, M. ;
Osterreichers, C. ;
Valencak, J. ;
Penz, M. ;
Kornek, G. ;
Hamilton, G. ;
Dragosics, B. ;
Chott, A. .
BRITISH JOURNAL OF CANCER, 2000, 83 (04) :454-457
[9]
High relapse rate in patients with MALT lymphoma warrants lifelong follow-up [J].
Raderer, M ;
Streubel, B ;
Woehrer, S ;
Puespoek, A ;
Jaeger, U ;
Formanek, M ;
Chott, A .
CLINICAL CANCER RESEARCH, 2005, 11 (09) :3349-3352
[10]
A PREDICTIVE MODEL FOR AGGRESSIVE NON-HODGKINS-LYMPHOMA [J].
SHIPP, MA ;
HARRINGTON, DP ;
ANDERSON, JR ;
ARMITAGE, JO ;
BONADONNA, G ;
BRITTINGER, G ;
CABANILLAS, F ;
CANELLOS, GP ;
COIFFIER, B ;
CONNORS, JM ;
COWAN, RA ;
CROWTHER, D ;
DAHLBERG, S ;
ENGELHARD, M ;
FISHER, RI ;
GISSELBRECHT, C ;
HORNING, SJ ;
LEPAGE, E ;
LISTER, TA ;
MEERWALDT, JH ;
MONTSERRAT, E ;
NISSEN, NI ;
OKEN, MM ;
PETERSON, BA ;
TONDINI, C ;
VELASQUEZ, WA ;
YEAP, BY .
NEW ENGLAND JOURNAL OF MEDICINE, 1993, 329 (14) :987-994